NovelStem International Corp. (NSTM) 股价，以美元计价

In July 2018 NovelStem International (previously Hollywood Media Corp.) purchased a 20% equity interest in Israel-based NewStem Ltd. NewStem is a developer of novel stem-cell-based diagnostic technology which can predict patients' resistance to chemotherapy to allow for better, targeted cancer treatments with the potential to reduce incidents of chemotherapy resistance. NovelStem also secured the right to increase its ownership in NewStem up to 33% based on the completion of up to $2 million in follow-on contributions over the next 18 months. NovelStem is currently a "dark" non SEC reporting company with 35.4 million common shares outstanding as of September 26, 2018. NewStem is a spinoff of Yissum, The Hebrew University of Jerusalem's technology-transfer company led by CEO Ayelet Dilion-Mashiah. NewStem's diagnostic solutions are based on the research of human haploid pluripotent stem cells (hHPSCs) by Professor Nissim Benvenisty of the Azrieli Center for Stem Cells and Genetic Research. NovelStem also owns a 50% interest in Netco Partners, a joint venture that owns the Net Force publishing franchise, which delves into the thrilling and fast-paced worlds of digital crimes, espionage and crypto-currencies. NovelStem is working to relaunch Net Force by seeking a new publishing agreement that would target the release of the first new book starting in 2019. More details are provided in press releases posted at www.novelstem.com.